[Valeant CEO Mike Pearson]REUTERS/Christinne Muschi After months of delays, a Senate hearing, and a percipitous stock fall, Valeant Pharmaceuticals finally filed their annual 10-k report to the SEC Friday morning. The document has been delayed multiple times as the comapny reviewed financial documents related to a speacialty pharmacy, Philior, associated with the company. According to the 10k, the relationship with Philador misstated $58 million in revenus and $33 million in profit during fiscal year 2014. Additionally, the company misstated revenue in the first quarter of 2015, which reduces revenue by $21 million but actually increases profits by $24 million. The company originally delayed the filing on March 21, stating they had created an ad hoc committee to review Valeant's financial statements. The committe then annouced they had completed their review on April 5. This has been a tumultous year for Valeant, which has had to deal with the scandal involving Philidor but also government pressure on its practice of puarchasing drugs and raising the price. _More to come..._ NOW WATCH: FORMER GREEK FINANCE MINISTER: The single largest threat to the global economy
 |
| READ THE ORIGINAL POST AT www.businessinsider.com |
